Quantum Molecular Resonance Treatment In Severe Dry Eye Disease

to evaluate efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED) in a follow-up period of 3 months.

University of Messina, Italy

Studio Oculistica Tedesco, Girifalco, Italy

in this prospective, interventional study 81 patients were divided in two treatment groups: in group 1, 43 patients (32 females, 11 males) received 4 treatment sessions of QMR using Rexon-eye device (Resono Ophthalmic, Trieste, Italy) at one-week intervals; whereas in group 2, 38 patients (26 females, 12 males) received sodium hyaluronate 0.15% and trehalose 3% (Thealoz Duo, Thea Pharma, France) 1 drop 4 times daily for 4 months.

Ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT) and tear osmolarity were evaluated at baseline, 1 and 3 months after treatment.

3 months after treatment, in group 1 there was a statistically significant reduction of the mean OSDI score (p=0.02), as well as both TBUT and NIBUT demonstrated statistically significant improvement (p< 0.0001 and p=0.01, respectively). Additionally, statistically significant changes of TMH, CFS, LLT, and tear osmolarity were observed (p=0.0002, p=0.01, p=0.002, and p< 0.0001; respectively).

In sub-group analysis, QMR treatment demonstrated a beneficial role to improve symptoms and tear film stability in both aqueous-deficient and evaporative DED patients.

QMR treatment is effective and safe to improve both signs and symptoms of DED in patients with severe disease.